France‑based Ocean Diagnostics completed a pilot clinical evaluation of a rapid blood test that identified sepsis pathogens and matched gold‑standard blood culture results at 100% while detecting additional pathogens missed by culture. The platform combines high‑volume sample prep, pan‑bacterial PCR, nanopore sequencing and a pathogen database, analyzing viable bacterial cells from up to 10 mL whole blood. Ocean Diagnostics plans clinical trials to support CE marking and will pursue FDA clearance, targeting a commercial turnaround time below five hours and an eventual 3.5‑hour goal.